- Dechra said it had acquired Ampharmco for $30m in cash.

Ampharmco (APC), founded in 1999 as a veterinary contract manufacturer, specialised in companion animal products and subsequently received FDA approval for two veterinary generic products, one of which, Gentamicin-Betamethasone Topical Spray, currently marketed by Dechra.

The other product, Carprofen Chewable Tablets, was currently marketed by another international animal health company.

APC would also provide Dechra with an FDA registered facility to manufacture solid dose, liquids, creams and ointments, which 'will significantly strengthen our manufacturing capabilities for the North American market,' the company said.

'APC also has a small pipeline of CAP products which will complement our existing US product portfolio,' it added.

At 9:46am: [LON:DPH] Dechra Pharmaceuticals PLC share price was +28p at 2998p

Story provided by